Ignite Creation Date:
2024-05-06 @ 8:07 PM
Last Modification Date:
2024-10-26 @ 3:21 PM
Study NCT ID:
NCT06261021
Status:
RECRUITING
Last Update Posted:
2024-04-25
First Post:
2024-01-30
Brief Title:
Study to Evaluate the Efficacy of Ruxolitinib 15 Cream in Adult Subjects with Discoid Lupus Erythematosus
Sponsor:
Innovaderm Research Inc
Organization:
Innovaderm Research Inc
Study Overview
Official Title:
A Phase 2 Single-Blind Intraindividual Study to Evaluate the Efficacy of Ruxolitinib 15 Cream in Adult Subjects with Discoid Lupus Erythematosus
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a single-blind intraindividual study to evaluate the efficacy of ruxolitinib 15 cream in adult subjects with discoid lupus erythematosus
Detailed Description:
This study is being conducted to evaluate the efficacy safety and tolerability of ruxolitinib 15 cream in adult subjects with discoid lupus erythematosus
Approximately 20 subjects with discoid lupus erythematosus will apply ruxolitinib 15 cream twice daily on active lesions identified at Day 1 and any new lesions that appear for 24 weeks
Approximately 20 subjects with discoid lupus erythematosus will apply ruxolitinib 15 cream twice daily on active lesions identified at Day 1 and any new lesions that appear for 24 weeks
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None